A detailed history of Janus Henderson Group PLC transactions in Merus N.V. stock. As of the latest transaction made, Janus Henderson Group PLC holds 662,140 shares of MRUS stock, worth $63.5 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
662,140
Previous 829,558 20.18%
Holding current value
$63.5 Million
Previous $43.6 Million 42.87%
% of portfolio
0.03%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$52.33 - $94.15 $8.76 Million - $15.8 Million
-167,418 Reduced 20.18%
662,140 $62.3 Million
Q2 2025

Aug 14, 2025

BUY
$34.89 - $62.42 $15.6 Million - $27.9 Million
447,747 Added 117.27%
829,558 $43.6 Million
Q1 2025

May 15, 2025

BUY
$39.01 - $49.16 $14.1 Million - $17.7 Million
360,521 Added 1693.38%
381,811 $16.1 Million
Q4 2024

Feb 14, 2025

BUY
$41.45 - $54.5 $99,480 - $130,800
2,400 Added 12.71%
21,290 $895,000
Q3 2024

Nov 14, 2024

SELL
$47.19 - $58.84 $47.1 Million - $58.7 Million
-998,117 Reduced 98.14%
18,890 $943,000
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $18.9 Million - $28.6 Million
474,427 Added 87.44%
1,017,007 $60.2 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $323,354 - $597,795
11,536 Added 2.17%
542,580 $24.4 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $6.68 Million - $9.54 Million
332,756 Added 167.81%
531,044 $14.6 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $3.76 Million - $5.09 Million
186,674 Added 1607.32%
198,288 $4.68 Million
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $165,499 - $238,087
11,614 New
11,614 $213,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $4.4B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.